Results 61 - 70 of 258 : Previous 3 4 5 6 7 8 9 10 11 Next
If You're Gonna Sell, Sell Now
Thinking about tax strategies a little early can give you an edge.
A Drug to End Merck's Headache?
Merck presents promising data for its phase 3 migraine drug.
Merck and Schering Get Half a Divorce
The lovey-dovey duo ends their respiratory partnership.
Difficult Obstacles for SciClone
Is this drugmaker a day late and a dollar short?
FDA Sets a Higher Standard for Merck
Improved cholesterol levels aren't a good enough goal for these drugs.
Live From Bio: Investing in Orphan Drugs
There's money to be made in selling drugs to just a few people.
Revisiting the Wile E. Coyote Investing Method
Don't let a boulder hit you on the head.
More Cancer Issues for Johnson & Johnson
Definitely not a good side effect profile to have.
Some Insight Into Incyte's Data
A rheumatoid arthritis drug looks promising, according to early numbers.
Schering-Plough and J&J Score a Triple-Triple
Three phase 3 trials for a single drug? Oh my.
Legal Information © 1995 - 2008 The Motley Fool. All rights reserved.
Market Data provided by 
Terms & Conditions
RSS Headlines
Fool UK